Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Apellis Pharmaceuticals Inc APLS

Healthcare Biotechnology
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related... see more

Recent & Breaking News (NDAQ:APLS)

Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

GlobeNewswire 2 days ago

Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

GlobeNewswire 7 days ago

Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

GlobeNewswire 10 days ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 4, 2024

Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 1, 2024

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

GlobeNewswire March 11, 2024

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 6, 2024

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 27, 2024

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire February 26, 2024

Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Accesswire February 20, 2024

Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 20, 2024

Kuehn Law Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law Firm

Newsfile February 15, 2024

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 6, 2024

Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application

GlobeNewswire January 26, 2024

Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues

GlobeNewswire January 8, 2024

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 5, 2024

Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2024

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference

GlobeNewswire December 28, 2023

Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

GlobeNewswire December 14, 2023

EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting

GlobeNewswire December 11, 2023